156 related articles for article (PubMed ID: 36241556)
1. CPSF6-RARG-positive acute myeloid leukaemia resembles acute promyelocytic leukaemia but is insensitive to retinoic acid and arsenic trioxide.
Li J; Yan WZ; Bai LH; Jiang YF; Peng HL; Shen JK; Li RJ
Pathology; 2023 Apr; 55(3):407-412. PubMed ID: 36241556
[No Abstract] [Full Text] [Related]
2. A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.
Chen X; Wang F; Zhang Y; Teng W; Cao P; Ma X; Liu M; Tian Y; Wang T; Nie D; Zhang J; Liu H; Wang W
Br J Cancer; 2019 May; 120(11):1023-1025. PubMed ID: 30996344
[TBL] [Abstract][Full Text] [Related]
3. Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
Kulkarni UP; Selvarajan S; Lionel S; Prakash MA; Palani HK; Balasundaram N; Venkataraman A; Korula A; Devasia AJ; Fouzia NA; Janet NB; Nair SC; Abraham A; Mani T; Lakshmanan J; Arunachalam AK; Balasubramanian P; George B; Mathews V
Blood Cancer J; 2022 Jan; 12(1):22. PubMed ID: 35102152
[No Abstract] [Full Text] [Related]
4. A short report of novel
Song Y; Hou J; Wan L; Liu K; Zhou C; Wei S; Zhang G; Lin D; Li Y; Fang Q; Liu Y; Gong B; Gong X; Wang Y; Wei H; Wang J; Mi Y
Hematology; 2022 Dec; 27(1):518-522. PubMed ID: 35544458
[TBL] [Abstract][Full Text] [Related]
5. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Ng Liet Hing M; Ryland GL; Nguyen T; Tiong IS; Dun K; Ninkovic S; Nedumannil R; Westerman DA; Blombery PA; Chan KL; Bajel A
Br J Haematol; 2023 Aug; 202(4):893-896. PubMed ID: 37280781
[No Abstract] [Full Text] [Related]
6. First report of successful management of acute promyelocytic leukemia in a pregnant female with All-Trans-Retinoic Acid and Arsenic Trioxide-based induction regimen.
Khosla H; Jain A; Tatawadiya S; Prasad P; Nagpal K; Chaudhry S; Sharma M; Gupta DK; Saluja S; Jain A
Blood Cells Mol Dis; 2020 Nov; 85():102476. PubMed ID: 32688220
[No Abstract] [Full Text] [Related]
7. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
8. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
10. [Acute promyelocytic leukaemia].
Tøstesen M; Østergård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336301
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion].
Tøstesen M; Østgård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336300
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Li SY; Lu Y; Liu HC; Gang EJ; Le J; Qian SY; Tang SH; Si T; Pei RZ
Leuk Lymphoma; 2021 May; 62(5):1267-1270. PubMed ID: 33439058
[No Abstract] [Full Text] [Related]
13. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
14. Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Wiernik PH
Br J Haematol; 2023 Jan; 200(2):126-127. PubMed ID: 36342482
[TBL] [Abstract][Full Text] [Related]
15. Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid.
Singh C; Saini M; Jain A; Lad D; Prakash G; Khadwal A; Naseem S; Malhotra P
Blood Cancer J; 2024 Jan; 14(1):14. PubMed ID: 38238308
[No Abstract] [Full Text] [Related]
16. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.
Strocchio L; Gurnari C; Santoro N; Putti MC; Micalizzi C; Zecca M; Cuccurullo R; Girardi K; Diverio D; Testi AM; Lo-Coco F; Locatelli F
Br J Haematol; 2019 Apr; 185(2):360-363. PubMed ID: 30028005
[No Abstract] [Full Text] [Related]
17. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
18. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
19. Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
Imagawa J
Leuk Lymphoma; 2018 Dec; 59(12):3013-3015. PubMed ID: 29616847
[No Abstract] [Full Text] [Related]
20. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
Russell N; Burnett A; Hills R; Betteridge S; Dennis M; Jovanovic J; Dillon R; Grimwade D;
Blood; 2018 Sep; 132(13):1452-1454. PubMed ID: 30097508
[No Abstract] [Full Text] [Related]
[Next] [New Search]
